C - Chemistry – Metallurgy – 12 – N
Patent
C - Chemistry, Metallurgy
12
N
C12N 15/12 (2006.01) A61K 31/7088 (2006.01) A61K 38/00 (2006.01) C07K 14/705 (2006.01) C07K 16/28 (2006.01) C07K 17/00 (2006.01) C12N 5/10 (2006.01) C12Q 1/68 (2006.01) G01N 33/68 (2006.01)
Patent
CA 2410489
An isolated polynucleotide encoding a novel potassium channel polypeptide, KCNQ5, that is expressed primarily in brain and skeletal muscle is described. The new polypeptide has been cloned and isolated from a human brain cDNA library and is a member the KCNQ family of potassium channels. The provided human KCNQ5 nucleic acid sequence and encoded polypeptide can be employed for diagnostic, screening and therapeutic uses. Moreover, the hKCNQ5 polypeptide can be used to assay for KCNQ5 potassium channel modulators, which can be utilized in the treatment of neurological, neurophysiological, neuropsychological and neuroaffective diseases, conditions and disorders, including, but not limited to, acute and chronic pain, migraine, acute stroke, dementia, vascular dementia, trauma, epilepsy, amyelotrophic lateral sclerosis (ALS), multiple sclerosis (MS), Parkinson's Disease, learning and cognitive disorders, and neurophysiological disorders including anxiety disorders, depression, bipolar disorders, sleep disorders, addiction, and eating disorders.
L'invention concerne un polynucléotide isolé codant un nouveau polypeptide canal potassium, KCNQ5, qui est principalement exprimé dans le cerveau et le muscle squelettique. Le nouveau polypeptide a été cloné et isolé à partir d'une bibliothèque d'ADNc de cerveau humain et appartient à la famille KCNQ canaux potassium. La séquence d'acide nucléique KCNQ5 humain et le polypeptide codé peuvent servir à établir un diagnostic, un procédé de dépistage ou encore des thérapies. De plus, le polypeptide hKCNQ5 peut être utilisé pour doser les modulateurs du KCNQ5 canal potassium, qui peut servir dans le traitement d'affections neuroaffectives, neuropsychologiques, neurophysiologiques, ou neurologiques et aussi des conditions et des troubles, comprenant mais pas exhaustivement, les douleurs chroniques aiguës, la migraine, les crises aiguës, la démence, la démence vasculaire, les traumatismes, l'épilepsie, la sclérose latérale amyélotrophique (ALS), la sclérose en plaques (MS), la maladie de Parkinson, les troubles cognitifs, les troubles de l'apprentissage et les troubles neurophysiologiques comprenant des troubles anxieux, la dépression, des troubles bipolaires, des troubles du sommeil, de la dépendance et de l'alimentation.
Boissard Christopher G.
Dworetzky Steven I.
Gribkoff Valentin K.
Ramanathan Chandra S.
Trojnacki Joanne T.
Bristol-Myers Squibb Company
Gowling Lafleur Henderson Llp
LandOfFree
Human kcnq5 potassium channel, methods and compositions thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Human kcnq5 potassium channel, methods and compositions thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Human kcnq5 potassium channel, methods and compositions thereof will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1905178